Dyskinesias  >>  lisdexamfetamine  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lisdexamfetamine / Generic mfg.
NCT00556296: Phase 3 Randomized Double-Blind Placebo-Controlled Study of NRP104 in Children Aged 6-12 With ADHD

Completed
3
297
US
NRP104, NRp104, Placebo
New River Pharmaceuticals, Shire
Attention Deficit Hyperactivity Disorder
 
09/05
NCT00334880: Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

Completed
3
420
US
NRP104
New River Pharmaceuticals
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders
 
11/06
NCT00337285: An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Completed
3
349
US
Vyvanse (lisdexamfetamine dimesylate), NRP104
New River Pharmaceuticals, Shire
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders
11/07
06/08

Download Options